"FDA Grants Full Approval to Groundbreaking Alzheimer's Drug, Offering Hope to Patients and Caregivers"

The FDA has granted full approval for a new drug called Leqembi, making it the first drug of its kind to slow cognitive decline in people with early stages of Alzheimer's disease. The approval means that Medicare can now cover the cost of treatment, making it more widely available. Leqembi, administered intravenously every two weeks, targets amyloid beta, the main component of amyloid plaques found in the brains of Alzheimer's patients. While the drug is not a cure, it can provide more time for individuals to maintain their independence and engage in activities they love. Concerns include potential brain swelling and bleeding, as well as the high cost of the drug.